Combo Active in Pretreated, Poor-Risk CLL MedPage Today NEW ORLEANS -- Patients with poor-risk chronic lymphocytic leukemia had significant improvement in survival when treated with an investigational small-molecule inhibitor plus rituximab, results of a placebo-controlled trial showed. As compared with the ... |
